Wall Street Zen Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Buy

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

Several other analysts also recently commented on SUPN. Cantor Fitzgerald upped their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of “Hold” and an average price target of $62.83.

Supernus Pharmaceuticals Trading Down 2.1%

NASDAQ SUPN opened at $46.20 on Friday. Supernus Pharmaceuticals has a 12-month low of $32.53 and a 12-month high of $59.68. The company has a fifty day simple moving average of $46.48 and a two-hundred day simple moving average of $49.24. The stock has a market cap of $2.68 billion, a P/E ratio of -90.59, a P/E/G ratio of 1.01 and a beta of 0.54.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Handelsbanken Fonder AB increased its stake in shares of Supernus Pharmaceuticals by 8.9% in the 2nd quarter. Handelsbanken Fonder AB now owns 20,716 shares of the specialty pharmaceutical company’s stock valued at $964,000 after purchasing an additional 1,700 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in Supernus Pharmaceuticals by 2.0% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 90,213 shares of the specialty pharmaceutical company’s stock worth $4,196,000 after purchasing an additional 1,759 shares in the last quarter. Empowered Funds LLC purchased a new position in Supernus Pharmaceuticals during the first quarter worth approximately $264,000. Bank of America Corp DE grew its holdings in Supernus Pharmaceuticals by 37.2% in the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock valued at $36,918,000 after purchasing an additional 193,479 shares during the period. Finally, California State Teachers Retirement System grew its holdings in Supernus Pharmaceuticals by 26.9% in the first quarter. California State Teachers Retirement System now owns 67,686 shares of the specialty pharmaceutical company’s stock valued at $3,499,000 after purchasing an additional 14,347 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.